Noelle Frey, MD
University of Pennsylvania · Abramson Cancer Center at Penn Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Noelle Frey, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:53 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07451054 · CD45BE-HSPC + CART-45 CellsUniversity of Pennsylvania · recruiting · B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation, T-Cell Non-Hodgkin Lymphoma · principal investigator
- Ph1NCT05945849 · CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AMLUniversity of Pennsylvania · recruiting · Leukemia, Myeloid, Acute · principal investigator
- Ph1NCT05037669 · Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and LymphomaUniversity of Pennsylvania · withdrawn · Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma · principal investigator
- Ph1NCT03620058 · CART22 Alone or in Combination With huCART19 for ALLUniversity of Pennsylvania · active not recruiting · Chemotherapy Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT02935543 · CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALLUniversity of Pennsylvania · terminated · Leukemia, Acute Lymphoblastic · principal investigator
- Ph1NCT02588456 · Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic LeukemiaUniversity of Pennsylvania · terminated · Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT02167360 · Study of Efficacy and Safety of CTL019 in Adult ALL PatientsAbramson Cancer Center at Penn Medicine · withdrawn · B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT02030847 · Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic LeukemiaUniversity of Pennsylvania · completed · Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options · principal investigator
- Ph2NCT01747486 · Dose Optimization Trial of CD19 Redirected Autologous T CellsUniversity of Pennsylvania · completed · Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL · principal investigator
- Ph1/Ph2NCT01486784 · A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic LeukemiaAbramson Cancer Center at Penn Medicine · terminated · Acute Myelogenous Leukemia · principal investigator
- Ph1/Ph2NCT01113502 · Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)Abramson Cancer Center at Penn Medicine · terminated · Acute Myelogenous Leukemia (AML) · principal investigator
- Ph1NCT01029366 · CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to ChemotherapyUniversity of Pennsylvania · completed · Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in acute myeloid leukemia.